Dr. Sequist Discusses the IMPRESS Trial
Lecia V. Sequist, MD, MPH, associate professor of medicine, Massachusetts General Hospital, discusses the IMPRESS trial, which was presented at the 2015 World Conference on Lung Cancer.
Sequist says the results were unexpected, since since continued gefitinib with chemotherapy were thought to have a stronger benefit. However, the results showed no difference. Tony Mok, MD, who presented the study, found that patients with a T790M resistance mutation did not benefit from continuing gefitinib. Those without the mutation showed an improved progression-free survival.
Lecia V. Sequist, MD, MPH, associate professor of medicine, Massachusetts General Hospital, discusses the IMPRESS trial, which was presented at the 2015 World Conference on Lung Cancer. This was a randomized study where patients were given front-line gefitinib. At the time of progression, they were randomized to either continue gefitinib with chemotherapy or to stop gefitinib and receive placebo with chemotherapy.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
